Related Experiment Video
Updated: Jul 28, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma
Shawn Dason1, Kristine Lacuna2, Raquibul Hannan3
1Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Abstract:
Oligometastatic renal cell carcinoma (OM-RCC) refers to patients who have limited (typically up to 5) metastatic lesions. Although management principles may overlap, OM-RCC is distinguishable from oligoprogressive RCC, which describes progression of disease to a limited number of sites while receiving systemic therapy. Cytoreductive nephrectomy and metastasectomy are common surgical considerations in OM-RCC, and indications are discussed in this review. It is evident that stereotactic ablative radiotherapy is effective in RCC and is being applied increasingly in the oligometastatic setting. Finally, we will review advances in systemic therapy and the role of active surveillance before the initiation of systemic therapy.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Urinary Tract Calculi III: Medical Management
Chronic Kidney Disease IV: Nursing Management
Treatment Resistant Cancers

